A strain of Lactobacillus plantarum JYLP-116 for improving the function of GLP-1, bacterial agent and application thereof

Abstract

The present invention relates to the field of microbial technology, and in particular to a plant lactobacillus JYLP-116 that improves the function of GLP-1, a bacterial agent and an application thereof. The plant lactobacillus JYLP-116 was deposited in the General Microbiological Center of the China Microbiological Culture Collection Administration Committee on January 18, 2024, with a deposit address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and a deposit number of CGMCC No. 29660. The plant lactobacillus JYLP-116 provided by the present invention inhibits the activity of dipeptidyl peptidase-4 and synergistically regulates the content of multiple hormones, while reducing hyperglycemia caused by obesity, and alleviates liver damage and body oxidation caused by obesity.

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to a lactobacillus plantarum JYLP-116 strain for improving the function of GLP-1, a bacterial agent and applications thereof. Background Art

[0002] Obesity refers to a certain degree of obvious overweight and excessive fat layer. It is a state caused by excessive accumulation of body fat, especially triglycerides. With the rapid development of social economy, people's dietary level has gradually improved, and high-fat and high-sugar eating habits have caused more and more people to become obese. Obesity is not only an independent disease, but also an important cause of many chronic diseases such as cardiovascular and cerebrovascular diseases, various cancers, type 2 diabetes and hypertension. In recent years, obesity has caused serious harm to people's health and has become a focus of public health attention.

[0003] The invention patent with application number 202311630313.0 discloses an animal Bifidobacterium lactis subspecies strain and its use. The animal Bifidobacterium lactis subspecies strain can inhibit the differentiation of 3T3-L1 preadipocytes, thereby effectively inhibiting fat deposition and having a weight loss function; it can inhibit the activity of blood glucose DPP-4 and α-glucosidase in rats with insulin resistance and sugar / lipid metabolism disorder model induced by alloxan by producing higher levels of DPP-4 inhibitors and α-glucosidase inhibitors, and can stimulate NCI-H716 cells to secrete high levels of GLP-1, thereby having the effect of lowering blood sugar. The animal Bifidobacterium lactis subspecies strain disclosed in the patent can only inhibit fat deposition and reduce blood sugar in rats with insulin resistance and sugar / lipid metabolism disorder model, but cannot reduce body weight and alleviate liver damage and body oxidation caused by obesity. Summary of the invention

[0004] In view of the technical problem that existing probiotics for reducing hyperglycemia caused by obesity cannot reduce body weight and alleviate liver damage, increased blood lipids and body oxidation caused by obesity, the present invention provides a plant lactobacillus JYLP-116 with improved GLP-1 function, a bacterial agent and its application, which inhibits the activity of dipeptidyl peptidase-4 and synergistically regulates the contents of multiple hormones, thereby reducing hyperglycemia and hyperlipidemia caused by obesity and alleviating liver damage and body oxidation caused by obesity.

[0005] In a first aspect, the present invention provides a strain of Lactobacillus plantarum ( Lactiplantibacillus plantarum ) JYLP-116, Lactobacillus plantarum JYLP-116 was deposited in the General Microbiology Center of China Microbiological Culture Collection Administration on January 18, 2024. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 29660.

[0006] In a second aspect, the present invention provides a bacterial agent containing the above-mentioned Lactobacillus plantarum JYLP-116, and the preparation method comprises the following steps:

[0007] Step 1: Activate Lactobacillus plantarum JYLP-116 in MRS liquid medium;

[0008] Step 2: inoculating the activated Lactobacillus plantarum JYLP-116 into an MRS liquid culture medium for aerobic culture to obtain a bacterial liquid of Lactobacillus plantarum JYLP-116;

[0009] Step 3: centrifuging and washing the bacterial solution of Lactobacillus plantarum JYLP-116 in sequence, and then resuspending the solution in 15 wt % reconstituted skim milk to obtain a bacterial suspension of Lactobacillus plantarum JYLP-116;

[0010] Step 4: adjusting the concentration of the bacterial suspension of Lactobacillus plantarum JYLP-116, and then freeze-drying to obtain bacterial powder of Lactobacillus plantarum JYLP-116;

[0011] Step 5: Mix the bacterial powder of Lactobacillus plantarum JYLP-116 with maltodextrin to obtain a bacterial agent of Lactobacillus plantarum JYLP-116.

[0012] Furthermore, the MRS liquid culture medium includes the following raw materials: 10g of peptone, 5g of beef extract powder, 5g of sodium acetate trihydrate, 2g of potassium dihydrogen phosphate heptahydrate, 1mL of Tween 80, 0.05g of manganese sulfate tetrahydrate, 2g of triammonium citrate, 20g of glucose, 0.2g of magnesium sulfate heptahydrate, and 1000mL of distilled water. The MRS liquid culture medium is a culture medium that has been subjected to pH adjustment and sterilization treatment in sequence, the target value of pH adjustment is 6.8, the temperature of sterilization treatment is 121°C, the pressure of sterilization treatment is 0.1MPa, and the time of sterilization treatment is 20min.

[0013] Furthermore, in step 2, the inoculation amount of activated Lactobacillus plantarum JYLP-116 is 1 wt %; the aerobic culture temperature is 37° C., and the aerobic culture duration is 24 h.

[0014] Further, in step 4, the concentration of the bacterial suspension of Lactobacillus plantarum JYLP-116 was adjusted to 1.0×10 10 -2.0×10 10 cfu / mL.

[0015] Further, in step 5, the number of bacteria of the Lactobacillus plantarum JYLP-116 agent is 1.0×10 8 cfu / g.

[0016] In a third aspect, the present invention also provides a use of the bacterial agent of Lactobacillus plantarum JYLP-116 as described above in the preparation of a drug for treating obesity.

[0017] Furthermore, the bacterial agent of Lactobacillus plantarum JYLP-116 is used to alleviate liver damage and hyperlipidemia caused by obesity. The bacterial agent of Lactobacillus plantarum JYLP-116 can reduce the content of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), and triglyceride (TG), and alleviate liver damage caused by obesity.

[0018] Furthermore, the bacterial agent of Lactobacillus plantarum JYLP-116 is used to reduce high blood sugar caused by obesity. On the one hand, the bacterial agent of Lactobacillus plantarum JYLP-116 can directly promote insulin secretion and reduce blood sugar content. On the other hand, it can inhibit the activity of dipeptidyl peptidase-4, reducing its ability to decompose glucagon-like peptide-1 (GLP-1), indirectly enhancing insulin secretion, inhibiting glucagon secretion, and reducing blood sugar content.

[0019] Furthermore, the bacterial agent of Lactobacillus plantarum JYLP-116 is used to enhance the body's antioxidant capacity. The bacterial agent of Lactobacillus plantarum JYLP-116 can increase the content of catalase (CAT) and superoxide dismutase (SOD), reduce the content of malondialdehyde (MDA), relieve oxidative stress caused by increased blood sugar, and enhance the body's antioxidant capacity.

[0020] The beneficial effects of the present invention are:

[0021] The plant lactobacillus JYLP-116 and the bacterial agent thereof provided by the present invention can alleviate liver damage caused by obesity and reduce the risk of cardiovascular and cerebrovascular diseases caused by a high-fat diet by reducing the contents of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), and triglyceride (TG); promote insulin secretion, inhibit the activity of dipeptidyl peptidase-4, and reduce blood sugar content; increase the contents of catalase (CAT) and superoxide dismutase (SOD), reduce the content of malondialdehyde (MDA), alleviate oxidative stress caused by increased blood sugar, and enhance the body's antioxidant capacity; reduce the content of plasma metabolic endotoxin (LPS), and alleviate kidney damage caused by obesity. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0023] Figure 1It is a bar chart of aspartate aminotransferase (AST) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0024] Figure 2 It is a bar chart of alanine aminotransferase (ALT) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0025] Figure 3 It is a bar chart of the total cholesterol (TC) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0026] Figure 4 It is a bar graph of triglyceride (TG) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0027] Figure 5 It is a bar graph of malondialdehyde (MDA) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0028] Figure 6 It is a bar graph of the catalase (CAT) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0029] Figure 7 It is a bar chart of the superoxide dismutase (SOD) content of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0030] Figure 8 It is a bar chart of insulin levels of mice in the blank group, model group, low treatment group and high treatment group in Example 4. Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0031] Fig. 9 It is a bar graph of plasma metabolic endotoxin (LPS) levels of mice in the blank group, model group, low treatment group and high treatment group in Example 4, Note: Different lowercase letters in the same column indicate significant differences (P < 0.05), n = 12.

[0032] Fig.10 It is a bar chart of the dipeptidyl peptidase-4 (DPP-4) enzyme inhibition rate of mice in the blank group, model group, low treatment group and high treatment group in Example 5, Note: Different lowercase letters in the same column indicate significant differences (P < 0.05), n = 12.

[0033] Fig.11 It is a bar graph of the glucagon-like peptide-1 (GLP-1) levels of mice in the blank group, model group, low treatment group and high treatment group in Example 5, Note: Different lowercase letters in the same column indicate significant differences (P < 0.05), n = 12. DETAILED DESCRIPTION

[0034] In order to enable those skilled in the art to better understand the technical solutions in the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0035] Example 1 Isolation, screening and identification of strains

[0036] 1. Strain screening and purification

[0037] (1-1) Strain source: yeast, collected in Dezhou City, Shandong Province, China in July 2023.

[0038] (1-2) Sample preparation:

[0039] S1: Add 1 g of leavener into a conical flask containing 99 mL of sterile saline, stir and shake at 4° C. for 30 min to obtain a mixed solution for later use.

[0040] S2: Use sterile saline to dilute the mixture obtained in step S1 by 10 times in a gradient manner to 10% of the original concentration. -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 times, and mark them in sequence as sample 1, sample 2, sample 3, sample 4, sample 5, sample 6, sample 7, and keep them for later use.

[0041] (1-3) Prepare MRS plate culture medium containing 0.5wt% CaCO3:

[0042] Mix 10 g of peptone, 5 g of beef powder, 5 g of sodium acetate trihydrate, 2 g of potassium hydrogen phosphate heptahydrate, 1 mL of Tween 80, 0.05 g of manganese sulfate tetrahydrate, 2 g of triammonium citrate, 20 g of glucose, 0.2 g of magnesium sulfate heptahydrate, 5 g of calcium carbonate, 15 g of agar, and 1000 mL of distilled water, adjust the pH to 6.8, heat and mix, and then sterilize at 121° C. and 0.1 MPa for 20 min to obtain a sterilized MRS medium;

[0043] Pour the sterilized MRS culture medium into a plate and let it cool to obtain the MRS plate culture medium.

[0044] (1-4) Cultivation: Samples 1 to 7 were spread on MRS plate culture medium using a spreading rod and cultured at 37°C under anaerobic conditions for 48 h.

[0045] (1-5) Selecting colonies:

[0046] Twenty-two single colonies were selected according to the following colony characteristics: diameter 1-2 mm, round colony, neat edges, slightly white color with a bulge in the middle, and a large calcium dissolution circle.

[0047] (1-6) Separation and purification:

[0048] The twenty-two single colonies obtained in steps (1-5) were inoculated onto MRS plate culture medium by the streak method, cultured at 37°C under anaerobic conditions for 48 hours, and the streak purification was repeated 2-3 times. Then, twenty-two purified single colonies were picked and placed in glycerol tubes and stored at -70°C. The twenty-two purified single colonies stored in the glycerol tubes were marked as alternative strain 1 to alternative strain 22.

[0049] 2. Screening of functional strains

[0050] (2-1) Preparation of fermentation broth of candidate strains

[0051] 2-1-1: Preparation of MRS liquid culture medium: Mix 10 g of peptone, 5 g of beef powder, 5 g of sodium acetate trihydrate, 2 g of potassium hydrogen phosphate heptahydrate, 1 mL of Tween 80, 0.05 g of manganese sulfate tetrahydrate, 2 g of triammonium citrate, 20 g of glucose, 0.2 g of magnesium sulfate heptahydrate, and 1000 mL of distilled water, adjust the pH to 6.8, stir well, and sterilize at 121°C, 0.1 MPa for 20 min to obtain MRS liquid culture medium.

[0052] 2-1-2: Activate candidate strains 1 to 22 respectively in the MRS liquid culture medium prepared in step 2-1-1.

[0053] 2-1-3: The activated alternative strains 1 to 22 were inoculated into MRS liquid culture medium at a 1% inoculation rate, and then cultured aerobically at 37° C. for 24 h to obtain fermentation broths of the alternative strains 1 to 22.

[0054] (2-2) Screening of strains with the ability to scavenge active oxygen

[0055] 400 μL of fermentation broth of candidate strain 1-candidate strain 22 and 1 mL of 0.2 mM DPPH ethanol solution were respectively added to culture tubes and mixed, and placed at room temperature for 60 min in a light-proof environment to obtain reaction solutions of candidate strain 1-candidate strain 22, and the absorbance A of each reaction solution at 517 nm was detected using a visible light spectrophotometer.

[0056] 400 μL of distilled water and 1 mL of 0.2 mM DPPH ethanol solution were added to the culture tube and mixed, and placed in a light-proof environment at room temperature for 60 min to obtain a blank reaction solution. The absorbance value A0 of the blank reaction solution at 517 nm was detected using a visible light spectrophotometer.

[0057] The active oxygen scavenging rates of the fermentation broths of candidate strains 1 to 22 were calculated and compared according to the following formula:

[0058] Active oxygen scavenging rate % = ((A0-A) / A0) × 100%;

[0059] Among them, the active oxygen scavenging rates of the fermentation broths of the alternative strains 1 to 3 are higher than those of the fermentation broths of the other alternative strains. The active oxygen scavenging rates of the fermentation broths of the alternative strains 1 to 3 are shown in Table 1.

[0060] Table 1 Active oxygen scavenging rate of fermentation broth of candidate strains 1 to 3

[0061]

[0062] As shown in Table 1, the active oxygen scavenging rate of the fermentation broth of the alternative strain 1 is the highest, which is 72%, indicating that the active oxygen scavenging function of the alternative strain 1 is the best.

[0063] 3. Strain identification

[0064] The single colony of candidate strain 1 separated and purified in step (1-6) was sent for identification by Sangon Biotech (Shanghai) Co., Ltd. During the identification process, the primers used were as follows:

[0065] 27F: 5′-AGAGTTTGATCCTGGCTCAG-3′ (as shown in sequence 1);

[0066] 1492R: 5'-CTACGGCTACCTTGTTACGA-3' (as shown in sequence 2).

[0067] The gene sequence of candidate strain 1 is as follows:

[0068]

[0069] The identification result is: the strain is Lactobacillus plantarum Lactiplantibacillus plantarum .

[0070] The identified strain was named Lactobacillus plantarum JYLP-116 and sent to the General Microbiology Center of China Microbiological Culture Collection Administration for preservation. The preservation information is as follows:

[0071] Classification name: Lactobacillus plantarum Lactiplantibacillus plantarum , deposit date: January 18, 2024, deposit unit: General Microbiology Center of China Microbiological Culture Collection Administration, deposit address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, deposit number: CGMCC No.29660.

[0072] Example 2 Preparation of bacterial agent

[0073] A bacterial agent containing Lactobacillus plantarum JYLP-116, the preparation method of which comprises the following steps:

[0074] Step 1: Prepare MRS liquid culture medium: mix 10 g of peptone, 5 g of beef extract powder, 5 g of sodium acetate trihydrate, 2 g of dipotassium hydrogen phosphate heptahydrate, 1 mL of Tween 80, 0.05 g of manganese sulfate tetrahydrate, 2 g of triammonium citrate, 20 g of glucose, 0.2 g of magnesium sulfate heptahydrate, and 1000 mL of distilled water, adjust the pH to 6.8, heat and mix, and then sterilize at 121°C and 0.1 MPa for 20 min to obtain MRS liquid culture medium.

[0075] Step 2: Activate Lactobacillus plantarum JYLP-116 in MRS liquid culture medium.

[0076] Step 3: Inoculate the activated Lactobacillus plantarum JYLP-116 at an inoculum amount of 1 wt % into MRS liquid culture medium and culture it aerobically at 37° C. for 24 hours to obtain a bacterial liquid of Lactobacillus plantarum JYLP-116.

[0077] Step 4: centrifuge the bacterial solution of Lactobacillus plantarum JYLP-116 and collect the bacterial cells, then wash the bacterial cells with sterile physiological saline, and resuspend the washed bacterial cells in 15wt% reconstituted skim milk to obtain a bacterial suspension of Lactobacillus plantarum JYLP-116.

[0078] Step 5: Adjust the concentration of the bacterial suspension of Lactobacillus plantarum JYLP-116 to 1.0×10 10 cfu / mL, and then freeze-dried to obtain the bacterial powder of Lactobacillus plantarum JYLP-116.

[0079] Step 6: Mix the powder of Lactobacillus plantarum JYLP-116 with maltodextrin to obtain a bacterial cell count of 1.0×10 8 cfu / g of the bacterial agent of Lactobacillus plantarum JYLP-116.

[0080] Example 3 Effects of Lactobacillus plantarum JYLP-116 on body weight, blood sugar and food intake of mice

[0081] 1. Establishment of mouse obesity model

[0082] Select healthy male C57BL / 6J mice aged 6-8 weeks purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd., first use maintenance feed to adapt to feeding for one week, and weigh each mouse after one week of adaptive feeding, and then divide the mice into two groups of equal number, and mark them as experimental group and control group respectively. The maintenance feed of the experimental group mice was replaced with a high-fat feed containing 60wt% fat, and the control group mice continued to use the maintenance feed for feeding. The experimental group mice and the control group mice were fed continuously for more than twelve weeks according to the same feeding method. During the continuous feeding period, each mouse in each group was weighed every week, and the average weight of each group of mice was calculated respectively, wherein the high-fat feed was purchased from Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd., and the item number was XTHF45. The obesity of the experimental group mice was calculated according to the following formula. When the obesity of the experimental group mice exceeded 20%, it was considered that the modeling was successful, and the mice with successful modeling were obese model mice.

[0083] .

[0084] In the above formula, the average weight of the experimental group mice and the average weight of the control group mice refer to the average weight of the experimental group mice and the average weight of the control group mice fed for the same number of consecutive weeks.

[0085] 2. Treatment of obese mice

[0086] Twelve healthy mice without obesity were selected as the blank group, and thirty-six obese model mice were selected and randomly divided into three groups, each with twelve mice, as the model group, low treatment group and high treatment group. Each group of mice was treated according to the following requirements:

[0087] Blank group: treated with 100µL 100mg / L gelatin aqueous solution by gavage only;

[0088] Model group: treated with 100 µL 100 mg / L gelatin aqueous solution by gavage only;

[0089] Low treatment group: only 1 mL of low-concentration bacterial coating solution was used for gavage treatment. The low-concentration bacterial coating solution was a mixture of the plant lactobacillus JYLP-116 agent prepared in Example 2 and 100 mg / L gelatin aqueous solution. The number of plant lactobacillus JYLP-116 cells in the low-concentration bacterial coating solution was 1×10 4 cfu / mL;

[0090] High treatment group: only 1 mL of high concentration bacterial coating solution was used for gavage treatment. The high concentration bacterial coating solution was a mixture of the plant lactobacillus JYLP-116 agent prepared in Example 2 and 100 mg / L gelatin aqueous solution. The number of plant lactobacillus JYLP-116 cells in the high concentration bacterial coating solution was 1×10 9 cfu / mL;

[0091] The preparation method of the gelatin aqueous solution is as follows: add 0.1 g of gelatin to 1000 mL of pure water, and then heat the solution in a water bath at 60° C. to completely dissolve the gelatin.

[0092] The drinking water of each group of mice was changed every two days, and they continued to be fed maintenance feed during the treatment period, which lasted for 6 weeks.

[0093] 3. Phenotypic index detection

[0094] a. Weight test

[0095] The mice in the blank group, obesity model group, low treatment group and high treatment group were weighed before and after treatment, and the weight growth rate of mice in each group was calculated. The weight of mice in each group before treatment, the weight after treatment and the weight growth rate of mice in each group are shown in Table 2.

[0096] Table 2 Body weight test results of mice in each group

[0097]

[0098] Note: Different lowercase letters in the same column indicate significant differences ( P <0.05), n=12.

[0099] As shown in Table 2, the body weights of obese mice in the low treatment group and the high treatment group after treatment were lower than that of obese mice in the model group after treatment, indicating that the body weights of obese mice were significantly reduced after treatment with Lactobacillus plantarum JYLP-116.

[0100] b. Feed intake statistics

[0101] The daily food intake of mice in the blank group, obesity model group, low treatment group and high treatment group before and after treatment was statistically analyzed. The statistical results are shown in Table 3.

[0102] Table 3 Statistical results of daily food intake of mice in each group

[0103]

[0104] Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0105] As shown in Table 3, the daily food intake of obese mice in the low treatment group and the high treatment group after treatment was significantly lower than that of obese mice in the model group, indicating that treatment with Lactobacillus plantarum JYLP-116 can increase the satiety of mice and reduce their daily food intake.

[0106] c. Blood glucose test

[0107] After six weeks of treatment, the mice in each group were fasted overnight and blood was collected from the tail vein to measure the blood glucose of the mice. The blood glucose of the mice in each group before and after treatment is shown in Table 4.

[0108] Table 4 Blood glucose test results of mice in each group

[0109]

[0110] Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0111] As shown in Table 4, the blood glucose levels of obese mice in the low treatment group and the high treatment group after treatment were significantly lower than those of the model group, indicating that Lactobacillus plantarum JYLP-116 can reduce the blood glucose level in obese mice.

[0112] Example 4

[0113] After six weeks of treatment, mice in each group were fasted overnight. On the second day, 1 mL of blood was collected from the eye sockets of mice. The collected blood was centrifuged at 3500 rpm for 15 min, and the upper serum samples were frozen. In addition, 500 μL of blood was collected from the heart of mice and placed in an anticoagulant tube containing sodium heparin for routine blood tests and biochemical index detection. The kit produced by Nanjing Jiancheng Bioengineering Co., Ltd. was used to determine the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), and triglyceride (TG) in the heart blood samples of mice in each group in strict accordance with the instructions. The measurement results are shown in Figure 1-4 As shown in Table 5; the contents of malondialdehyde (MDA), catalase (CAT), and superoxide dismutase (SOD) in the serum samples of each group of mice were measured. The results are shown in Figure 5-7 As shown in Table 6; the ELISA kit of Shanghai ELISA Biological Co., Ltd. was used to detect the plasma insulin and plasma metabolic endotoxin (LPS) content of each group of mice in strict accordance with the instructions. The test results are shown in Figure 8-9 And as shown in Table 7.

[0114] Table 5 Test results of heart blood samples from mice in each group

[0115]

[0116] Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0117] As shown in Table 5, the AST, ALT, TC and TG levels of the low-treatment group and the high-treatment group were significantly lower than those of the model group, indicating that the bacterial agent of Lactobacillus plantarum JYLP-116 can effectively alleviate liver damage caused by obesity in mice and reduce blood lipid levels.

[0118] Table 6 Test results of serum samples from each group of mice

[0119]

[0120] Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0121] As shown in Table 6, the CAT and SOD levels of the low-treatment group and the high-treatment group were significantly higher than those of the model group, and the MDA level was significantly lower than that of the model group, indicating that the bacterial agent of Lactobacillus plantarum JYLP-116 can effectively alleviate the oxidative stress caused by increased blood sugar in obese mice and enhance the body's antioxidant capacity.

[0122] Table 7 Results of plasma insulin and plasma metabolic endotoxin content detection in each group of mice

[0123]

[0124] Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0125] As shown in Table 7, the insulin levels in the low treatment group and the high treatment group were significantly higher than those in the model group, indicating that the bacterial agent of Lactobacillus plantarum JYLP-116 can increase the secretion of insulin and improve the ability of obese mice to decompose blood sugar. The LPS levels in the low treatment group and the high treatment group were significantly lower than those in the model group, indicating that Lactobacillus plantarum JYLP-116 can effectively alleviate renal damage caused by obesity in mice.

[0126] Example 5 Effects of the bacterial preparation of Lactobacillus plantarum JYLP-116 on DPP-4 enzyme activity and GLP-1 hormone levels in mice

[0127] The DPP-4 ELISA kit purchased from Shanghai ELISA and the GLP-1 kit purchased from Nanjing Jiancheng Biotechnology were used to detect the DDP-4 enzyme activity and GLP-1 hormone level in the serum samples left in Example 4. The detection steps were strictly carried out in accordance with the instructions of the corresponding kits. The test results are as follows: Figure 10-11 and as shown in Table 8.

[0128] Table 8 Detection results of DPP-4 enzyme activity and GLP-1 hormone levels in serum samples of mice in each group

[0129]

[0130] Note: Different lowercase letters in the same column indicate significant differences (P<0.05), n=12.

[0131] As shown in Table 8, after treatment with the bacterial agent of Lactobacillus plantarum JYLP-116, the DPP-4 enzyme activity in obese mice was significantly inhibited and the GLP-1 hormone level was increased, indicating that the bacterial agent of Lactobacillus plantarum JYLP-116 can improve the anti-sugar ability of obese mice.

[0132] Although the present invention has been described in detail with reference to the accompanying drawings and in combination with the preferred embodiments, the present invention is not limited thereto. Without departing from the spirit and essence of the present invention, a person of ordinary skill in the art may make various equivalent modifications or substitutions to the embodiments of the present invention, and these modifications or substitutions shall be within the scope of the present invention. Any person of ordinary skill in the art may easily think of changes or substitutions within the technical scope disclosed by the present invention, and these shall be within the scope of protection of the present invention.

Claims

1. A strain of Lactobacillus plantarum that improves the function of GLP-1 ( Lactiplantibacillus plantarum )JYLP-116, It is characterized in that Lactobacillus plantarum JYLP-116 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on January 18, 2024. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 29660.

2. A bacterial agent containing the plant lactobacillus JYLP-116 as claimed in claim 1, It is characterized in that The preparation method comprises the following steps: Step 1: Activate Lactobacillus plantarum JYLP-116 in MRS liquid medium; Step 2: inoculating the activated Lactobacillus plantarum JYLP-116 into an MRS liquid culture medium for aerobic culture to obtain a bacterial liquid of Lactobacillus plantarum JYLP-116; Step 3: centrifuging and washing the bacterial solution of Lactobacillus plantarum JYLP-116 in sequence, and then resuspending the solution in 15 wt % reconstituted skim milk to obtain a bacterial suspension of Lactobacillus plantarum JYLP-116; Step 4: adjusting the concentration of the bacterial suspension of Lactobacillus plantarum JYLP-116, and then freeze-drying to obtain bacterial powder of Lactobacillus plantarum JYLP-116; Step 5: Mix the bacterial powder of Lactobacillus plantarum JYLP-116 with maltodextrin to obtain a bacterial agent of Lactobacillus plantarum JYLP-116.

3. The bacterial agent of Lactobacillus plantarum JYLP-116 according to claim 2, It is characterized in that The MRS liquid culture medium includes the following raw materials: 10 g of peptone, 5 g of beef extract powder, 5 g of sodium acetate trihydrate, 2 g of dipotassium hydrogen phosphate heptahydrate, 1 mL of Tween 80, 0.05 g of manganese sulfate tetrahydrate, 2 g of triammonium citrate, 20 g of glucose, 0.2 g of magnesium sulfate heptahydrate, and 1000 mL of distilled water.

4. The bacterial agent of Lactobacillus plantarum JYLP-116 as claimed in claim 2, It is characterized in that In step 2, the inoculation amount of activated Lactobacillus plantarum JYLP-116 is 1 wt %; the aerobic culture temperature is 37° C., and the aerobic culture duration is 24 h.

5. The bacterial agent of Lactobacillus plantarum JYLP-116 according to claim 2, It is characterized in that In step 4, the concentration of the bacterial suspension of Lactobacillus plantarum JYLP-116 was adjusted to 1.0×10 10 -2.0×10 10 cfu / mL.

6. The bacterial agent of Lactobacillus plantarum JYLP-116 according to claim 2, It is characterized in that In step 5, the number of bacteria of the Lactobacillus plantarum JYLP-116 inoculum is 1.0×10 8 cfu / g.

7. Use of the bacterial agent of Lactobacillus plantarum JYLP-116 according to any one of claims 2 to 6 in the preparation of a drug for treating obesity.

8. The use according to claim 7, It is characterized in that Obesity medications are used to relieve liver damage and high blood lipids caused by obesity.

9. The use according to claim 7, It is characterized in that Obesity medications are used to lower high blood sugar levels that can result from obesity.

10. The use according to claim 7, It is characterized in that Drugs used to treat obesity are used to enhance the body's antioxidant capacity.

Images